Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

High prevalence of non-receipt of cancer-directed therapy among the oldest old persists independent of healthcare accessibility: A population-based analysis of 82,864 patients.

Cancer epidemiology·2026

Same author

Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19).

Cancer research and treatment·2026

Same author

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

International journal of clinical oncology·2026

Same author

Neutrophil-to-lymphocyte ratio half reduction as a surrogate of molecular response in polycythemia vera treated with ropeginterferon alfa-2b.

Therapeutic advances in hematology·2026

Same author

Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study.

Annals of hematology·2026

Same author

Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.

Lung cancer (Amsterdam, Netherlands)·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Nilotinib-induced interstitial lung disease.

Se-Il Go¹, Won Sup Lee, Gyeong-Won Lee

¹Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer Center, Institute of Health Sciences, Gyeongsang National University School of Medicine, 90 Chilam-dong, Jinju, 660-702, Korea.

International Journal of Hematology

|July 24, 2013

Summary

Nilotinib, a leukemia drug, can cause interstitial lung disease (ILD). This case report highlights the importance of considering this rare but serious side effect in CML patients.

More Related Videos

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Related Experiment Videos

Last Updated: May 9, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

Oncology
Pulmonology
Pharmacology

Background:

Nilotinib is a second-generation tyrosine kinase inhibitor used for chronic myeloid leukemia (CML).
It is effective in imatinib-resistant CML and approved for newly diagnosed patients.
This report details a rare adverse event associated with nilotinib therapy.

Observation:

A 67-year-old female with Philadelphia chromosome-positive (Ph(+)) CML developed chronic cough.
Chest X-ray showed bilateral lung consolidations.
A diagnosis of nilotinib-induced interstitial lung disease (ILD) was confirmed via lung biopsy.

Findings:

The patient had received nilotinib for approximately 3 years without prior adverse effects.
Interstitial lung disease (ILD) was diagnosed as a complication of nilotinib treatment.
The patient showed a significant positive response to corticosteroid therapy.

Implications:

This is the first reported case of nilotinib-induced ILD in a patient with Ph(+) CML.
Physicians should consider nilotinib-induced ILD in patients with unexplained lung abnormalities.
Early diagnosis and treatment with corticosteroids may be crucial for managing this potentially fatal complication.